Douglas Miehm
Stock Analyst at RBC Capital
(1.21)
# 3,528
Out of 4,876 analysts
48
Total ratings
35.14%
Success rate
-10.34%
Average return
Main Sectors:
Stocks Rated by Douglas Miehm
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BHC Bausch Health Companies | Maintains: Sector Perform | $8.5 → $10 | $6.41 | +56.01% | 20 | May 2, 2025 | |
| BLCO Bausch + Lomb | Maintains: Outperform | $18 → $17 | $12.07 | +40.85% | 13 | Apr 4, 2025 | |
| ONCY Oncolytics Biotech | Maintains: Outperform | $6 → $5 | $0.72 | +594.44% | 1 | Mar 10, 2025 | |
| LGND Ligand Pharmaceuticals | Maintains: Outperform | $141 → $143 | $115.72 | +23.58% | 5 | Dec 11, 2024 | |
| AUPH Aurinia Pharmaceuticals | Maintains: Outperform | $13 → $8 | $8.63 | -7.30% | 9 | Feb 16, 2024 |
Bausch Health Companies
May 2, 2025
Maintains: Sector Perform
Price Target: $8.5 → $10
Current: $6.41
Upside: +56.01%
Bausch + Lomb
Apr 4, 2025
Maintains: Outperform
Price Target: $18 → $17
Current: $12.07
Upside: +40.85%
Oncolytics Biotech
Mar 10, 2025
Maintains: Outperform
Price Target: $6 → $5
Current: $0.72
Upside: +594.44%
Ligand Pharmaceuticals
Dec 11, 2024
Maintains: Outperform
Price Target: $141 → $143
Current: $115.72
Upside: +23.58%
Aurinia Pharmaceuticals
Feb 16, 2024
Maintains: Outperform
Price Target: $13 → $8
Current: $8.63
Upside: -7.30%